Edition:
United Kingdom

Jaguar Health Inc (JAGX.OQ)

JAGX.OQ on NASDAQ Stock Exchange Capital Market

0.16USD
20 Apr 2018
Change (% chg)

$-0.01 (-3.08%)
Prev Close
$0.17
Open
$0.16
Day's High
$0.17
Day's Low
$0.16
Volume
320,640
Avg. Vol
1,399,749
52-wk High
$0.99
52-wk Low
$0.11

Chart for

About

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuti... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $14.22
Shares Outstanding(Mil.): 67.70
Dividend: --
Yield (%): --

Financials

  JAGX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.04 -- --
ROI: -- 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Jaguar Health Files For Resale Of Up To 29.4 Mln Shares Common Stock By The Selling Shareholders

* JAGUAR HEALTH INC FILES FOR RESALE OF UP TO 29.4 MILLION SHARES COMMON STOCK BY THE SELLING SHAREHOLDERS - SEC FILING Source : https://bit.ly/2qOl6Fa Further company coverage: (Reuters.Briefs@thomsonreuters.com)

20 Apr 2018

BRIEF-Jaguar Health Says Unit Signed Agreement With ADAP Crisis Task Force

* JAGUAR INC SAYS NAPO PHARMACEUTICALS HAS SIGNED AN AGREEMENT WITH ADAP CRISIS TASK FORCE

10 Apr 2018

BRIEF-Jaguar Health Inc Files For Non-Timely 10-K With U.S. SEC

* JAGUAR HEALTH INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC Source text: (https://bit.ly/2GQ2TRx) Further company coverage:

02 Apr 2018

BRIEF-Jaguar Health Says Entered Securities Purchase Agreement With Chicago Venture Partners - SEC Filing​

* JAGUAR HEALTH - ‍ON FEB 26, CO ENTERED SECURITIES PURCHASE AGREEMENT WITH CHICAGO VENTURE PARTNERS - SEC FILING​

02 Mar 2018

BRIEF-Jaguar Health Says Unit Napo Pharmaceuticals Signs Deal With Transition Patient Services To Establish Nationwide Pilot "Mytesi Direct" Program

* JAGUAR HEALTH - UNIT NAPO PHARMACEUTICALS SIGNS DEAL WITH TRANSITION PATIENT SERVICES TO ESTABLISH NATIONWIDE PILOT “MYTESI DIRECT” PROGRAM

02 Mar 2018

BRIEF-Jaguar Health Files For Resale Or Other Disposition Of Up To 6.02 Mln Shares Of Voting Common Stock

* JAGUAR HEALTH INC FILES FOR RESALE OR OTHER DISPOSITION OF UP TO 6.02 MILLION SHARES OF VOTING COMMON STOCK - SEC FILING Source text: [http://bit.ly/2BJoioW] Further company coverage:

31 Jan 2018

BRIEF-Jaguar Health Provides Updates Regarding Programs

* JAGUAR HEALTH PROVIDES UPDATES REGARDING COMMERCIAL, EDUCATIONAL & PRODUCT DEVELOPMENT PROGRAMS AND 2017 RESULTS FOR MYTESI SINCE MERGER (AUGUST–DECEMBER 2017) Source text for Eikon: Further company coverage:

22 Jan 2018

BRIEF-Jaguar Health Says Unit Entered Amendment To Note Purchase Agreement

* JAGUAR HEALTH - ON DEC 29, 2017, UNIT ENTERED AMENDMENT TO NOTE PURCHASE AGREEMENT & NOTES WITH EACH OF PURCHASERS PARTY TO AGREEMENT DATED MARCH 1, 2017

02 Jan 2018

BRIEF-Jaguar Health ‍Enters Collaboration Agreement With SEED For Equilevia​

* JAGUAR HEALTH INC - ‍ENTERED COLLABORATION AGREEMENT WITH SEED MENA BUSINESSMEN SERVICES FOR EQUILEVIA​

14 Dec 2017

BRIEF-Jaguar Health enters share purchase agreement

* JAGUAR HEALTH ENTERS SHARE PURCHASE AGREEMENT FOR 2 MILLION SHARES AND COMMON STOCK PURCHASE AGREEMENT RELATING TO A 10 MILLION SHARE EQUITY LINE OFFERING WITH L2 CAPITAL, LLC

27 Nov 2017

Earnings vs. Estimates